Emcure Pharmaceuticals
Emcure Pharmaceuticals is a leading Indian pharmaceutical company committed to developing, manufacturing, and marketing a broad range of pharmaceutical products across major therapeutic areas. With a focus on research and development, innovation, and quality, Emcure aims to address unmet medical needs and improve healthcare accessibility worldwide. The company has a strong presence in over 70 countries, with advanced manufacturing and R&D capabilities, and a diverse portfolio including generics, biosimilars, and novel therapies.
Industries
Nr. of Employees
Very Large (1000+)
Emcure Pharmaceuticals
Products
Thermostable mRNA vaccine platforms
Self‑amplifying mRNA vaccine development and manufacturing with thermostability‑focused delivery systems for prophylactic use.
Therapeutic biologics (INN examples)
Commercial manufacture and supply of therapeutic biologics including erythropoietin, filgrastim, peg‑filgrastim and pegaspargase.
Complex generic and specialty formulations
Range of commercial formulations including modified‑release oral products, long‑acting injectables, lipid nanoparticle and liposomal formulations and ready‑to‑use injectables.
Thermostable mRNA vaccine platforms
Self‑amplifying mRNA vaccine development and manufacturing with thermostability‑focused delivery systems for prophylactic use.
Therapeutic biologics (INN examples)
Commercial manufacture and supply of therapeutic biologics including erythropoietin, filgrastim, peg‑filgrastim and pegaspargase.
Complex generic and specialty formulations
Range of commercial formulations including modified‑release oral products, long‑acting injectables, lipid nanoparticle and liposomal formulations and ready‑to‑use injectables.
Services
Contract development and manufacturing (CDMO)
Process development, technology transfer, scale‑up and commercial manufacturing of APIs, formulations and biologics for third‑party clients.
API development and commercial supply
End‑to‑end API services including discovery-scale chemistry, process optimization, chiral synthesis, peptide APIs and commercial GMP manufacture.
Formulation development and manufacturing
Development and manufacture of oral solids/liquids, modified‑release products, nasal delivery, topical systems, lipid nanoparticle and liposomal formulations, long‑acting injectables and ready‑to‑use injectables.
Biologics development and manufacturing
Process and product development for biologics and vaccines using mammalian and microbial platforms, pegylation processes and mRNA vaccine production.
Regulatory and dossier support
Preparation and filing of global dossiers and DMFs, regulatory interaction support and facilitation of inspections/approvals across major jurisdictions.
Contract development and manufacturing (CDMO)
Process development, technology transfer, scale‑up and commercial manufacturing of APIs, formulations and biologics for third‑party clients.
API development and commercial supply
End‑to‑end API services including discovery-scale chemistry, process optimization, chiral synthesis, peptide APIs and commercial GMP manufacture.
Formulation development and manufacturing
Development and manufacture of oral solids/liquids, modified‑release products, nasal delivery, topical systems, lipid nanoparticle and liposomal formulations, long‑acting injectables and ready‑to‑use injectables.
Biologics development and manufacturing
Process and product development for biologics and vaccines using mammalian and microbial platforms, pegylation processes and mRNA vaccine production.
Regulatory and dossier support
Preparation and filing of global dossiers and DMFs, regulatory interaction support and facilitation of inspections/approvals across major jurisdictions.
Expertise Areas
- Formulation development for oral, injectable and topical products
- API process development and scale-up
- Bioprocessing and biomanufacturing (mammalian and microbial)
- mRNA therapeutics and vaccine platform development
Key Technologies
- Flow chemistry and continuous processing
- Asymmetric (chiral) synthesis
- Solid‑phase and solution‑phase peptide synthesis
- Photochemistry for API transformations